Jeong Mo Bae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jeong Mo Bae has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
- Gyeong Hoon Kang
Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
50 shared publications - Andrew J. Lee
Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea
21 shared publications - Baekgyu Choi
Korea Advanced Institute of Science and Technology (KAIST) 1 Department of Biological Sciences Daejeon, Republic of Korea
21 shared publications - Chul-Hwan Lee
Seoul National University
21 shared publications - Gou Young Koh
Center for Vascular Research, Institute for Basic Science and Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
21 shared publications - Inkyung Jung
Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea
21 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
Utility of LymphoTrack for clonality testing in formalinfixed, paraffin-embedded tissue: integrated panel- and specimen-level comparison with fragment analysis
- 13 November 2026
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
Open AccessUtility of LymphoTrack for clonality testing in formalinfixed, paraffin-embedded tissue: integrated panel- and specimen-level comparison with fragment analysis
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S3 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
Locus-specific regulation of CD73 m6A methylation decreases its expression
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S3 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
Locus-specific regulation of CD73 m6A methylation decreases its expression
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S2 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
KRAS mutation and MAPK signaling increase CD73 expression
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S2 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
KRAS mutation and MAPK signaling increase CD73 expression
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S1 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
Characterization of the m 6 A landscape associated with KRAS
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S1 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
Characterization of the m 6 A landscape associated with KRAS
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S10 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
The KRAS-METTL3-CD73 axis is associated with CD73-high malignant cell states in human CRC
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S10 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
The KRAS-METTL3-CD73 axis is associated with CD73-high malignant cell states in human CRC
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S6 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
The METTL3-CD73 axis attenuates human CD8+ T-cell effector function
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S6 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
The METTL3-CD73 axis attenuates human CD8+ T-cell effector function
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S7 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
The KRAS-METTL3-CD73 axis regulates tumor growth and tumor immune remodeling
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S7 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
The KRAS-METTL3-CD73 axis regulates tumor growth and tumor immune remodeling
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S4 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
IGF2BP3 regulates CD73 expression as an m6A reader protein
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S4 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
IGF2BP3 regulates CD73 expression as an m6A reader protein
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S5 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
TEAD4 is a binding partner of the methyltransferase complex
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S5 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
TEAD4 is a binding partner of the methyltransferase complex
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
Supplementary Table S1 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer
Supplementary Table S1 from KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer